Authors
Martin Lagging, Ana I Romero, Johan Westin, Gunnar Norkrans, Amar P Dhillon, Jean‐Michel Pawlotsky, Stefan Zeuzem, Michael Von Wagner, Francesco Negro, Solko W Schalm, Bart L Haagmans, Carlo Ferrari, Gabriele Missale, Avidan U Neumann, Elke Verheij‐Hart, Kristoffer Hellstrand, DITTO‐HCV Study Group
Publication date
2006/12
Journal
Hepatology
Volume
44
Issue
6
Pages
1617-1625
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Description
Plasma from 173 patients with HCV genotype 1 infection was analyzed for IP‐10 levels prior to treatment with pegylated interferon‐α‐2a and ribavirin. Significantly lower IP‐10 levels were observed in patients achieving a rapid viral response (RVR) (P < .0001), even in those with body mass index (BMI) ≥ 25 kg/m2 (P = .004) and with baseline viral load ≥ 2 million IU/mL (P = .001). Similarly, significantly lower IP‐10 levels were observed in patients obtaining a sustained viral response (SVR) (P = .0002), including those having higher BMI (P < .05), higher viral load (P = .0005), and both higher BMI and viral load (P < .03). In multivariate logistic regression analyses, a low IP‐10 value was independently predictive of both RVR and SVR. A baseline cutoff IP‐10 value of 600 pg/mL yielded a negative predictive value (NPV) of 79% (19/24) for all genotype 1–infected patients, which was comparable with that observed …
Total citations
20072008200920102011201220132014201520162017201820192020202120222023202411131218363727252018162461421